HCV Vaccines
EASL: Telbivudine Effective for Hepatitis B Patients Selected with Roadmap
- Details
- Category: HBV Treatment
- Published on Tuesday, 08 May 2012 00:00
- Written by Liz Highleyman
Telbivudine (Tyzeka) is an effective treatment for chronic hepatitis B with minimal emergence of drug resistance when using the "Roadmap" algorithm for selecting appropriate patients and deciding when to add other agents, according to a trio of studies presented at the 47th International Liver Congress (EASL 2012) last month in Barcelona.
EASL: Having Only Wild-type Hepatitis B Virus Predicts Response to Interferon
- Details
- Category: HBV Treatment
- Published on Friday, 04 May 2012 00:00
- Written by Liz Highleyman
Chronic hepatitis B patients who do not have 2 common HBV mutations are more likely to achieve undetectable viral load and HBsAg loss when treated with pegylated interferon, according to study findings presented at the 47th International Liver Congress (EASL 2012) last month in Barcelona.
Canadian Researchers Make Progress in Quest for Hepatitis C Vaccine
- Details
- Category: HCV Vaccines
- Published on Tuesday, 21 February 2012 00:00
- Written by Press Release
Researchers at the University of Albert say they have discovered a new vaccine candidate that stimulates immune response against all genotypes of hepatitis C virus (HCV). The variability of the virus enables it to elude the immune system and has so far hampered efforts to develop an effective vaccine.
Scientists Find Antibodies that Neutralize Multiple Strains of Hepatitis C Virus
- Details
- Category: HCV Vaccines
- Published on Tuesday, 10 April 2012 00:00
- Written by Press Release
As described in a report published in the April 4, 2012, online edition of Proceedings of the National Academy of Sciences, Erick Giang and Mansun Law from the Scripps Research Institute and colleagues have identified a set of antibodies with activity against 5 different antigenic regions on the E1E2 complex of the hepatitis C virus (HCV) outer envelope.
Experimental Hepatitis C Vaccine Triggers T-Cell Responses in Early Clinical Trial
- Details
- Category: HCV Vaccines
- Published on Tuesday, 10 January 2012 00:00
- Written by Liz Highleyman
An investigational adenovirus-based hepatitis C virus (HCV) vaccine induced sustained T-cell responses and cytokine production in a small Phase 1 study of healthy volunteers, according to findings reported in the January 4, 2012, issue of Science Translational Medicine.
More Articles...
- AASLD: Recombinant Hepatitis C Vaccine TG404 Shows Promise in Phase 2 Trial
- Discovery May Aid Development of Hepatitis C Vaccine
- Experimental HCV Vaccine Induces Broadly Neutralizing Antibodies in Mice and Monkeys
- New Phase 2b Study of Experimental Hepatitis C Vaccine ChronVac-C
- Researchers Report Promising Results from Studies of 3 Therapeutic HCV Vaccines
Web Design and Development by